Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials-Reference-Cited by-同舟云学术

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials

Published:2020 Issue:1 Volume:5 Page:e000659
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Eiger Daniel^ORCID,Franzoi Maria Alice,Pondé Noam,Brandão Mariana,de Angelis Claudia,Schmitt Nogueira Melanie,de Hemptinne Quentin,de Azambuja Evandro^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference47 articles.

1. Trastuzumab--mechanism of action and use in clinical practice;Hudis;N Engl J Med,2007

2. Twenty years of anti-HER2 therapy-associated cardiotoxicity;Pondé;ESMO Open,2016

3. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial;Earl;Lancet,2019

4. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial;Pivot;Lancet,2019

5. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic oncology Research Group (HORG);Mavroudis;Ann Oncol,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey;Breast Cancer Research and Treatment;2024-04-25

2. Involvement of kallikrein‐PAR2 ‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity;Cancer Science;2022-08-19

3. Breast Cancer with Associated Problems;Breast Cancer;2022

4. Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database;Drugs - Real World Outcomes;2021-09-15

5. Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis;Frontiers in Pharmacology;2021-08-18